VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Shanxi Xinghuacun Fen Wine Factory Co., Ltd. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Shanxi Xinghuacun Fen Wine Factory Co., Ltd.
600809 · Shanghai Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Shanxi Xinghuacun Fen Wine Factory Co., Ltd.'s moat claims, evidence, and risks.
View 600809 analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. leads (57 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 2 segments (73.7% in Mid-to-High Priced Liquor (>= RMB130/L)); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 5 moat types across 2 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Shanxi Xinghuacun Fen Wine Factory Co., Ltd.
Mid-to-High Priced Liquor (>= RMB130/L)
China premium baijiu (with focus on light-aroma baijiu) and mid-to-high priced spirits
China
Consumers and corporate/banquet demand via distributor/retail channels
Brand owner / distiller / wholesaler-distributor orchestrator
73.7%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Shanxi Xinghuacun Fen Wine Factory Co., Ltd. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Shanxi Xinghuacun Fen Wine Factory Co., Ltd. segments
Full profile >Mid-to-High Priced Liquor (>= RMB130/L)
Oligopoly
Other Liquor (value-tier baijiu and other spirits)
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.